Catalyst Pharmaceuticals (NASDAQ:CPRX) Upgraded to Buy by St

Catalyst Pharmaceuticals (NASDAQ:CPRX – Get Free Report) was upgraded by stock analysts at StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Friday. Several other analysts also recently commented on CPRX. Oppenheimer reaffirmed an “outperform” rating and set a $29.00 target price on shares of Catalyst Pharmaceuticals in a […]

Related Keywords

United States , America , Gary Ingenito , Brian Elsbernd , Dekabank Deutsche Girozentrale , Catalyst Pharmaceuticals , Analyst Recommendations For Catalyst Pharmaceuticals , Catalyst Pharmaceuticals Company Profile , Citigroup , Catalyst Pharmaceuticals Inc , Securities Exchange Commission , Cantor Fitzgerald , Cetera Advisors , Catalyst Pharmaceuticals Stock Performance , News Ratings For Catalyst Pharmaceuticals Daily , Institutional Investors Weigh In On Catalyst Pharmaceuticals , Comerica Bank , Virtu Financial , Ikarian Capital , Get Free Report , Exchange Commission , Bank Deutsche Girozentrale , Catalyst Pharmaceuticals Daily ,